Navigation Links
Drug That Lowers Resting Heart Rate Being Tested
Date:8/22/2007

Slower heartbeat linked to better cardiac outcome, scientists report

WEDNESDAY, Aug. 22 (HealthDay News) -- Can a drug designed solely to lower the resting heart rate improve treatment of cardiovascular conditions such as heart failure and coronary artery disease?

Answers to that question are expected next year from two major international trials that are testing the drug, said Dr. Jeffrey S. Borer, a professor of cardiovascular medicine at Weill Cornell Medical College in New York City.

The resting heart rate is the natural heartbeat measured after someone has been at rest for at least 10 minutes. A number of studies have linked a lower resting heart rate with better outcomes among those with cardiovascular disease, said Borer, a member of a group summarizing that evidence in the Aug. 28 issue of the Journal of the American College of Cardiology.

"That group of authors is involved in the evaluation of a new approach to heart rate slowing," Borer said. "It allows us for the first time to determine the pure effect of heart rate slowing on cardiac health."

The new approach uses a drug called ivabradine, which acts specifically on the cells of the sino-atrial node, the heart's natural pacemaker. Other drugs, such as beta blockers, can slow the resting heart rate, but they have other effects that blur the impact of a slowed resting heart rate.

Ivabradine has been approved in Europe for treatment of the chest pain called angina, but Servier Laboratories, the French company that markets the drug, has not applied for U.S. approval because it has no American subsidiary.

A footnote to the journal paper says all of its 10 authors "have received honoraria and many have received research grants from Servier Laboratories, and all authors are a part of the advisory board of ivabradine."

But those physicians, who describe themselves as members of the Heart Rate Working Group, are interested more in the general effects of resting heart rate than in any one drug, Borer said.

"We have been publishing for several years, because it became apparent that the potential importance of resting heart rate in determining prognosis is not so well understood," he said.

Perhaps the first study to indicate the possible importance of the resting heart rate was done during World War II, looking at the medical records of 25,000 army officers, Borer said. "Those with a resting heart rate above 100, about 300 of them, had a very poor long-term outcome," he noted.

In recent years, studies done in Norway have looked at possible beneficial effects of lowering the resting heart rate, using drugs such as beta blockers, Borer said. Studies of people with heart failure, the progressive loss of the heart's ability to pump blood, and of those who had suffered heart attacks, did show a benefit from slowing the heart rate, he added.

And a report on 25,000 cardiac patients done by Dr. Jean-Claude Tardif, of the Montreal Heart Institute, showed "a clear distinction in outcome based on resting heart rate," Borer added.

While there obviously are differences among individuals as to the best resting heart rate, "it is probably best if it is somewhat lower than 70" for an adult, he said.

Definitive evidence on the value of using a drug to lower the resting heart rate is expected from the two international trials now in progress, one including people with coronary artery disease, the other including people with heart failure, Borer said.

Results of those studies should be available by the late summer of 2008, he said.

More information

Learn more about the resting heart rate from the U.S. National Library of Medicine.



SOURCES: Jeffrey S. Borer, professor, cardiovascular medicine, Weill Cornell Medical College, New York City; Aug. 28, 2007, Journal of the American College of Cardiology


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Brisk Walking lowers memory loss in women
2. B Vitamin protects and lowers toxicity of Arthritis Drug
3. Estrogen lowers cancer risk
4. Lecithin lowers cholesterol absorption in body
5. Salt reduction lowers blood pressure
6. Tea Pill Lowers Cholesterol
7. Aspirin Lowers Leukemia Risk
8. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
9. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
10. Exercise lowers Risk of Ovarian Cancer
11. Fish rich diet lowers leptin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... ... 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and ... key role this treatment plays in protecting oral health, along with the benefits of ... who need a root canal in White Plains, NY or their second location in ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, ... co-exhibit with technology partners LG Business Solutions at ATARC Federal Mobile Computing ... Washington D.C., will provide education and examination into the mobility tools and technology ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... WAUKESHA, Wis. , March 27, 2017  A ... one of only four freestanding hospitals in the country ... in plastic and reconstructive surgery, concluded that the Surfacide ... effective and integral component in reducing bacterial pathogens not ... The findings were published at the American Burn Association,s ...
(Date:3/27/2017)... March 27, 2017 Medtec ... and more than 600 exhibitors from 70 countries ... and solutions that will advance the medical technology ... at the Messe Stuttgart, Stuttgart, Germany ... technology platform showcasing the key trends and insights ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
Breaking Medicine Technology: